US Patent 7928103 Compounds which modulate the CB2 receptor
Patent 7928103 was granted and assigned to Boehringer Ingelheim on April, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 27 Nov, 2023
Golden AI
Edits made to:
Article (+278 characters)
Article
Patent abstract
Compounds of formula (I) are disclosed. Compounds according to the invention are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
Edits on 19 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
David Smith Thomson0
Doris Riether0
Renee M. Zindell0
Edits on 22 Jul, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07928103 Compounds which modulate the CB2 receptor US Patent 7928103 Compounds which modulate the CB2 receptor
Infobox
Patent Number
079281030
Patent Number
79281030
Edits on 27 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
079281030
Date of Patent
April 19, 2011
0Patent Application Number
124449190
Date Filed
October 15, 2007
0Official Website
Patent Primary Examiner
Edits on 19 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 7 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07928103 Compounds which modulate the CB2 receptor
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07928103
Date of patent
April 19, 2011
Patent application number
12444919
Date Filed
October 15, 2007
Patent primary examiner
Find more entities like US Patent 7928103 Compounds which modulate the CB2 receptor
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.